Medicaid expansion could tax community health centers
The president of the Indiana Primary Health Care Association wants to double the number of federally qualified community health centers in Indiana in the next five years.
Health Care & Insurance
Articles
Repeated price cuts take glow off Endocyte IPO
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
Health insurers expect hit from reform rule
Major health insurers, including WellPoint, say a provision that requires them to spend a certain percentage of the premiums they collect on care-related costs will eat into earnings this year.
Arcadia reports smaller loss on increased revenue
The Indianapolis-based health care company lost $2.3 million on revenue of $26.2 million in its third fiscal quarter.
Daniels leads guvs’ health-care revolt
Boy does Gov. Mitch Daniels have an ultimatum for President Obama: Wave off the health reform law or else I’ll do nothing to help while it wreaks havoc on Hoosier citizens.
Recent successes don’t change Lilly’s outlook
Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.
Lilly collaboration with outside researchers yields first deal
Eli Lilly and Co.’s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it’s just the first of many such collaborations.
Eli Lilly CEO Lechleiter sees 2010 pay fall 22 percent
Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.
2010 compensation fell about 20 percent for top Lilly execs
Compensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as the company struggled to bring new medicines to market.
Endocyte again changes terms of public offering
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
Indiana Farm Bureau unveiling ads during Super Bowl
The insurer’s new campaign, developed by local advertising firm Young & Laramore, focuses on real-life situations amid a crowded field of competitors.
Panel OKs criminal checks on medical workers
Physicians, dentists, nurses, veterinarians, pharmacists and other medical workers would have to pay for a national criminal background check when applying for a state license under a bill pending with the Indiana Senate.
Health insurance brokers set for shakeout
Health insurance brokers, who match up employers with health insurance policies, are about to have a brighter light shone on the commissions they earn from insurers. The likely result: Commissions will fall or flatline and, eventually, fall away in favor of fee-based business models.
Struggling Lilly turns to antidepressant Cymbalta for lift
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
Baldwin & Lyons reports higher revenue, lower profit
Indianapolis-based insurer of car and truck fleets posts quarterly profit slightly lower than a year ago. Revenue, however, rose to $67.7 million, up from $60.8 million in 2009.
Lilly, Bristol-Myers halt enrollment in lung-cancer trial
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.
Potential competitor to Lilly drug shows promise in study
Sanofi-Aventis’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta, a study found.
Marcadia may fetch up to $537 million in sale
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
Judge’s ruling raises uncertainty for health care execs
After a federal judge in Florida struck down the entire health reform law, investors shrugged. But the uncertainty for executives in health care companies increased.
House passes measure fixing unemployment fund
The Indiana House approved a bill Monday to help fix the state's bankrupt unemployment insurance fund by reducing jobless benefits for some people and softening tax increases on businesses.